In a report released today, Clara Dong from Jefferies downgraded Astria Therapeutics to a Hold, with a price target of $13.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Clara Dong has given her Hold rating due to a combination of factors surrounding the acquisition of Astria Therapeutics by BCRX. The acquisition, valued at approximately $700 million, represents a strategic fit for BCRX’s existing hereditary angioedema (HAE) portfolio, particularly with the inclusion of Astria’s lead candidate, Navenibart. This long-acting injectable aligns well with BCRX’s current offerings and could enhance their market presence in the HAE space.
Despite the promising integration of Navenibart, which has shown strong efficacy in reducing HAE attacks, Clara Dong’s Hold rating reflects a cautious stance. The acquisition is expected to close in Q1 2026, and while there is potential for significant market share capture and revenue growth, the timeline for realizing these benefits extends into the future. Additionally, the competitive landscape, including existing treatments like Takhzyro, poses challenges that temper immediate expectations for the stock’s performance.